Skip to main
VCEL

Vericel (VCEL) Stock Forecast & Price Target

Vericel (VCEL) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vericel Corp is poised for significant revenue growth, driven by its MACI product line, which is projected to experience a high-teens to low-twenties percentage growth in top-line sales for FY26, in line with market expectations. The anticipated volume compound annual growth rate (CAGR) of approximately 14.8% combined with an annual average selling price (ASP) increase of 300 to 500 basis points supports a sustainable revenue trajectory. Additionally, the updated guidance for fourth-quarter revenue reflects a notable 26% quarter-over-quarter increase, further solidifying a favorable outlook on Vericel's financial performance.

Bears say

Vericel Corporation has revised its revenue expectations for its MACI product downward by approximately 200 basis points for fiscal years 2026 and 2027, indicating a diminished growth outlook. The company faces several risks, including potential lower adoption rates of MACI Arthro, slower sales in the burn care segment, and challenges related to its sales force expansion, all of which could adversely impact overall revenue performance. If Vericel fails to meet top-line expectations in upcoming quarters, there is a consensus that the company's shares could decline to historically low valuation levels.

Vericel (VCEL) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vericel and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vericel (VCEL) Forecast

Analysts have given Vericel (VCEL) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Vericel (VCEL) has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $57.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $57.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vericel (VCEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.